Organization score is the sum of its models
Insilico Medicine
Benefit
+0.17
Harm
0.00
Net Good
0.17
Timeline
- Benefit
- Harm
- Net
Models
| Rank | Model | Organization | Benefit | Harm | Net | Events | Last impact |
|---|---|---|---|---|---|---|---|
| 1 | Pharma.AI Internal Research Model Pharma.AI · internal / unreleased | Insilico Medicine | +0.17 | 0.00 | 0.17 | 1 | 3 Jun 2025 |
Domains
Events
Benefit3 Jun 2025
Rentosertib, an AI-designed TNIK inhibitor, posts Phase 2a IPF results
Insilico Medicine’s rentosertib (ISM001-055), discovered with generative models, met a Phase 2a safety endpoint in 71 IPF patients; the 60 mg daily arm showed a mean FVC gain of 98.4 ml versus a 20.3 ml decline on placebo.
Medicine & HealthverifiedTier 2 Notable+0.17
All events